Physician Views: Assessing the outlook for Novartis Entresto

Physician Views: Assessing the outlook for Novartis Entresto

Code: FW-20150708 | Published: Jul-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






Novartis has gained earlier than expected US approval for its new heart failure treatment Entresto, which is forecast to be the biggest new drug approval of 2015.


Much initial focus is on the pricing of Entresto, which at a cost of around $12 a day is significantly more expensive that current standard of care therapies. A months supply of generic enalapril - the comparator drug in Novartis approval-supporting PARADIGM-HF study - is available at a cost of around $4.


The Swiss company has earned the opportunity to price Entresto at a significant premium, argues Pfizers former head of R&D John LaMattina, given the mortality benefits it has demonstrated versus the most widely used current therapy option. Furthermore, Novartis has discussed the introduction of risk-sharing price agreements with select payers, which could see the price of the drug increase if Entresto reduces hospitalisation rates (Spotlight On: Can Novartis Entresto revive risk-share pricing deals in the post-Sovaldi US market).


This provides a tangible benchmark of the potential efficacy benefits that Entresto offers for the treatment of heart failure. Efficacy of the drug - and how it is viewed and utilised by physicians - will nevertheless come under scrutiny in light of its price.








Following FDA approval of Entresto (and in anticipation of EU approval), we are asking both US and EU5-based cardiologists and primary care practitioners the following questions


- Novartis Entresto (previously known as LCZ696) reduced cardiovascular death by 20 percent and overall mortality by 16 percent versus the ACE inhibitor enalapril in patients with heart failure and reduced ejection fraction in the PARADIGM-HF study. How do you characterise the clinical profile of Entresto?
- Versus approximately $4 for a months supply of enalapril, Novartis has confirmed that Entresto has a list price of $12.50 a day in the US. In relation to efficacy benefit is this price justified?
- What percentage of patients currently treated with ACE inhibitors or ARBs would you expect to switch to treatment with Entresto within 2 years of launch?
- How quickly do you expect Entresto to become the standard of care for the treatment of heart failure?
- What percentage of new start patients would you expect to be prescribing Entresto to two years after launch?



Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord